Dermatologic manifestations of COVID-19-associated multisystem inflammatory syndrome in children

Clin Dermatol. 2021 Mar-Apr;39(2):329-333. doi: 10.1016/j.clindermatol.2020.10.021. Epub 2020 Nov 1.

Abstract

Multisystem inflammatory syndrome in children (MIS-C) affects a small percentage of pediatric patients infected with COVID-19 and is characterized by fever, laboratory evidence of inflammation, multisystem involvement, and severe illness necessitating hospitalization. Skin findings are often present in these patients, and when initially compared with Kawasaki disease, they likely represent distinct phenomena and overall remain poorly characterized. In this retrospective review of 34 case reports and series, we identified cutaneous manifestations documented in 417 of 736 patients (57%) with MIS-C associated with COVID-19. "Rash" was the sole descriptor of skin findings in nearly half of patients. Case reports and smaller case series provided more detail, outlining a broad range of lesion morphologies (polymorphic, maculopapular, morbilliform, erythrodermic, urticarial, reticular, petechial, purpuric) in variable anatomic distribution. More thorough descriptions of dermatologic manifestations in patients with MIS-C are warranted to better characterize this syndrome, as they may lend important insight into pathogenic mechanisms of disease.

Publication types

  • Review

MeSH terms

  • COVID-19 / complications*
  • COVID-19 / diagnosis
  • Child
  • Humans
  • Retrospective Studies
  • Skin Diseases / etiology*
  • Systemic Inflammatory Response Syndrome / complications*
  • Systemic Inflammatory Response Syndrome / diagnosis

Supplementary concepts

  • pediatric multisystem inflammatory disease, COVID-19 related